Patents by Inventor Chris Tse

Chris Tse has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AUTOMATED TOTAL NAIL CARE SYSTEMS, DEVICES AND METHODS
    Publication number: 20240074560
    Abstract: A system, device and method for nail care is provided. The nail care system includes a shaping system, a polish removal system and/or a cuticle management system; a vision system; a nail polish application system; and a mobility system. The nail system may further include an accelerated drying system, a hand massage system, a nail identification/diagnosis/estimation of conditions system, an enclosure, a hand/foot rest system, a computer software system, a computer hardware system, a cartridge/pod system, and a multi-tool system. Related apparatuses, techniques and articles are also described.
    Type: Application
    Filed: October 29, 2020
    Publication date: March 7, 2024
    Inventors: Alexander Shashou, Justin Effron, Gabe Greeley, Marcus R. Williams, Margaret Mathieu, Lucile Driscoll, Lu Lyu, Charles C. Shortlidge, Peter Duerst, Douglas Stewart, Chris Casey, Ndungu Muturi, Ryan Wood, Zhi Teoh, Harald Quintus-Bosz, Jesse Gray, Matt Berlin, Juhi Kalra, Christine Noh, Oliver Zhang, Will Burke, Chris Evans, Allison Tse, Anthony Parker, Eric Maxwell, Genevieve Laing
  • Compounds for treatment of cystic fibrosis
    Patent number: 10130622
    Abstract: A corrector agent capable of stabilizing a newly synthesized cystic fibrosis transmembrane conductance regulator (CFTR) protein, useful in the treatment of cystic fibrosis.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: November 20, 2018
    Assignees: AbbVie S.á.r.l., Galapagos NV
    Inventors: Rhalid Akkari, Luke Jonathan Alvey, Xavier Marie Bock, Brian S. Brown, Pieter Isabelle Roger Claes, Marlon D. Cowart, Katja E. Conrath, Douglas Cyr, Elsa De Lemos, Gert Jules Hector De Wilde, Nicolas Desroy, Béranger Duthion, Gregory A. Gfesser, Romain Luc Marie Gosmini, Christopher Gaëtan Housseman, Koen Karel Jansen, Jianguo Ji, Philip R. Kym, Jean-Michel Lefrancois, Oscar Mammoliti, Christel Jeanne Marie Menet, Nuria Merayo Merayo, Gregory John Robert Newsome, Adeline Marie Elise Palisse, Sachin V. Patel, Mathieu Rafaël Pizzonero, Anurupa Shrestha, Elizabeth C. Swift, Chris Tse, Steven Emiel Van der Plas, Xueqing Wang
  • NAMPT and ROCK inhibitors
    Patent number: 10093624
    Abstract: Disclosed are isoindoline carboxamide, dihydropyrrolopyridine carboxamide, and dihydropyrrolopyrimidine carboxamide compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed. Disclosed are isoindoline carboxamide, dihydropyrrolopyridine carboxamide, and dihydropyrrolopyrimidine carboxamide compounds which inhibit the activity of ROCK, compositions containing the compounds and methods of treating diseases during which ROCK is expressed.
    Type: Grant
    Filed: October 12, 2015
    Date of Patent: October 9, 2018
    Assignee: AbbVie Inc.
    Inventors: Rick F. Clark, Michael L. Curtain, Todd M. Hansen, Howard R. Heyman, Helmut Mack, Michael Michaelides, Marina A. Pliushchev, Omar J. Shah, Bryan K. Sorensen, Ramzi Sweis, Chris Tse, Anil Vasudevan, Kevin R. Woller
  • NOVEL COMPOUNDS FOR TREATMENT OF CYSTIC FIBROSIS
    Publication number: 20170100386
    Abstract: A corrector agent capable of stabilizing a newly synthesized cystic fibrosis transmembrane conductance regulator (CFTR) protein, useful in the treatment of cystic fibrosis.
    Type: Application
    Filed: October 7, 2016
    Publication date: April 13, 2017
    Inventors: Rhalid Akkari, Luke Jonathan Alvey, Xavier Marie Bock, Brian S. Brown, Pieter Isabelle Roger Claes, Marlon D. Cowart, Katja E. Conrath, Douglas Cyr, Elsa De Lemos, Gert Jules Hector De Wilde, Nicolas Desroy, Béranger Duthion, Gregory A. Gfesser, Romain Luc Marie Gosmini, Christopher Gaëtan Housseman, Koen Karel Jansen, Jianguo Ji, Philip R. Kym, Jean-Michel Lefrancois, Oscar Mammoliti, Christel Jeanne Marie Menet, Nuria Merayo Merayo, Gregory John Robert Newsome, Adeline Marie Elise Palisse, Sachin V. Patel, Mathieu Rafaël Pizzonero, Anurupa Shrestha, Elizabeth C. Swift, Chris Tse, Steven Emiel Van der Plas, Xueqing Wang
  • MARKER TO PREDICT AND MONITOR RESPONSE TO AURORA KINASE B INHIBITOR THERAPY
    Publication number: 20160153052
    Abstract: The present invention relates to diagnostic assays useful in classification of patients for selection of cancer therapy with one or more Aurora kinase B inhibitors. In particular, the present invention relates to identifying the genetic defects in the CDKN2A locus which exhibit a heightened dependency on Aurora kinase activity, identifying patients eligible to receive Aurora kinase inhibitor therapy, either as monotherapy or as part of combination therapy, and monitoring patient response to such therapy.
    Type: Application
    Filed: December 2, 2015
    Publication date: June 2, 2016
    Applicant: AbbVie Inc.
    Inventors: Daniel Albert, Peter Ansell, Paul Hessler, Lloyd Lam, Chris Tse
  • NAMPT and rock inhibitors
    Patent number: 9302989
    Abstract: Disclosed are 1,3-dihydro-2H-isoindole compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of using the compounds to treat diseases during which NAMPT is expressed, e.g., cancer, metabolic disorders, and inflammatory disorders. Disclosed are 1,3-dihydro-2H-isoindole compounds which inhibit the activity of ROCK, compositions containing the compounds and methods of using the compounds to treat diseases during which ROCK is expressed, e.g., cancer, cardiovascular disorders, and inflammatory disorders.
    Type: Grant
    Filed: November 11, 2011
    Date of Patent: April 5, 2016
    Assignee: AbbVie Inc.
    Inventors: Michael L. Curtin, Bryan K. Sorensen, Howard R. Heyman, Richard F. Clark, Kevin R. Woller, Omar J. Shah, Michael Michaelides, Chris Tse, Anil Vasudevan, Helmut Mack, Todd M. Hansen, Ramzi Sweis, Marina A. Pliushchev
  • Nampt and Rock Inhibitors
    Publication number: 20160031880
    Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed. Disclosed are compounds which inhibit the activity of ROCK, compositions containing the compounds and methods of treating diseases during which ROCK is expressed.
    Type: Application
    Filed: October 12, 2015
    Publication date: February 4, 2016
    Applicant: ABBVIE INC.
    Inventors: Rick F. Clark, Michael L. Curtain, Todd M. Hansen, Howard R. Heyman, Helmut Mack, Michael Michaelides, Marina A. Pliushchev, Omar J. Shah, Bryan K. Sorensen, Ramzi Sweis, Chris Tse, Anil Vasudevan, Kevin R. Woller
  • NAMPT INHIBITORS
    Publication number: 20120122924
    Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.
    Type: Application
    Filed: November 11, 2011
    Publication date: May 17, 2012
    Applicant: ABBOTT LABORATORIES
    Inventors: Michael L. Curtin, Bryan K. Sorensen, Howard R. Heyman, Rick F. Clark, Michael Michaelides, Chris Tse
  • NAMPT AND ROCK INHIBITORS
    Publication number: 20120122842
    Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed. Disclosed are compounds which inhibit the activity of ROCK, compositions containing the compounds and methods of treating diseases during which ROCK is expressed.
    Type: Application
    Filed: November 11, 2011
    Publication date: May 17, 2012
    Applicant: Abbott Laboratories
    Inventors: Michael L. Curtin, Bryan K. Sorensen, Howard R. Heyman, Richard F. Clark, Kevin R. Woller, Omar J. Shah, Michael Michaelides, Chris Tse, Anil Vasudevan, Helmut Mack, Todd M. Hansen, Ramzi Sweis, Marina A. Pliushchev